BlackRock Fund Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-484,936
| Closed | -$1.44M | – | 4284 |
|
|
2016
Q3 | $1.44M | Buy |
484,936
+26,550
| +6% | +$46K | ﹤0.01% | 3206 |
|
|
2016
Q2 | $683K | Sell |
458,386
-574,316
| -56% | -$1.31M | ﹤0.01% | 3284 |
|
|
2016
Q1 | $3.82M | Sell |
1,032,702
-597,570
| -37% | -$3.7M | ﹤0.01% | 2876 |
|
|
2015
Q4 | $16.5M | Buy |
1,630,272
+119,669
| +8% | +$1.44M | ﹤0.01% | 2163 |
|
|
2015
Q3 | $20.5M | Buy |
1,510,603
+257,545
| +21% | +$4.59M | 0.01% | 1974 |
|
|
2015
Q2 | $23.8M | Sell |
1,253,058
-274,710
| -18% | -$5.95M | 0.01% | 2004 |
|
|
2015
Q1 | $40M | Buy |
1,527,768
+253,134
| +20% | +$6.44M | 0.01% | 1661 |
|
|
2014
Q4 | $26.7M | Buy |
1,274,634
+33,118
| +3% | +$835K | 0.01% | 1888 |
|
|
2014
Q3 | $41.4M | Buy |
1,241,516
+8,448
| +0.7% | +$262K | 0.01% | 1475 |
|
|
2014
Q2 | $39.6M | Buy |
1,233,068
+110,786
| +10% | +$4.13M | 0.01% | 1556 |
|
|
2014
Q1 | $51.8M | Sell |
1,122,282
-53,542
| -5% | -$3.14M | 0.02% | 1394 |
|
|
2013
Q4 | $83.4M | Buy |
1,175,824
+20,953
| +2% | +$1.6M | 0.03% | 983 |
|
|
2013
Q3 | $99M | Buy |
1,154,871
+160,096
| +16% | +$13.6M | 0.03% | 758 |
|
|
2013
Q2 | $63M | Buy |
+994,775
| New | +$52.8M | 0.02% | 1035 |
|
BlackRock Fund Advisors's AEGR Position: Q4 2016 in Review
BlackRock Fund Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 484,936 shares — an estimated $1.44M sold.
BlackRock Fund Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $99M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock Fund Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock Fund Advisors sold 484,936 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $1.44M.
- BlackRock Fund Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock Fund Advisors's Aegerion Pharmaceuticals position peaked at $99M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.